---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-086214"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2024-04-04T23:59:59+00:00"
generated_at: "2026-06-04T02:32:05.044873+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Zymeworks removes CFO Christopher Astle effective March 31; severance $425,000

## Summary
- Astle removed as CFO and principal accounting officer without cause, effective March 31, 2024.
- Severance package includes $425,000 lump sum (12 months' base salary) and 12 months of health benefits.
- Astle retains 92,369 vested stock options (90 days to exercise); 146,881 unvested options and 51,000 unvested RSUs forfeited.
- CEO Kenneth Galbraith serves as interim CFO; no permanent replacement announced.
- Separation agreement includes non-solicitation, non-competition, and confidentiality covenants.

## SEC filing metadata
- accession: 0001193125-24-086214
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2024-04-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000119312524086214/0001193125-24-086214-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000119312524086214/d821869d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-086214
- JSON: https://secwatch.observer/filing/0001193125-24-086214.json
- Plain text: https://secwatch.observer/filing/0001193125-24-086214.txt

## Key facts
- Executive change
  Christopher Astle was removed as Senior Vice President and Chief Financial Officer at Zymeworks Inc..
  - Action: removed
  - Role: Senior Vice President and Chief Financial Officer
  source text: As previously reported, effective March 31, 2024 (the “Separation Date”), Zymeworks Inc. (the “Company”) removed Dr. Christopher Astle from the positions of Senior Vice President and Chief Financial Officer, including as the Company’s principal financial officer and principal accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937653/000119312524086214/0001193125-24-086214-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.